A carregar...

A Phase I Clinical, Pharmacokinetic and Pharmacodynamic Study of Weekly or Every Three Week Ixabepilone and Daily Sunitinib in Patients with Advanced Solid Tumors

PURPOSE: To evaluate the safety, maximum tolerated dose (MTD), pharmacokinetics/pharmacodynamics, and early clinical activity of ixabepilone given either weekly or every three weeks in combination with daily sunitinib in patients with advanced solid tumors. EXPERIMENTAL DESIGN: Eligible patients rec...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Clin Cancer Res
Main Authors: Montero, Alberto J., Kwon, Deukwoo, Flores, Aurea, Kovacs, Krisztina, Trent, Jonathan, Benedetto, Pasquale, Rocha-Lima, Caio, Merchan, Jaime R.
Formato: Artigo
Idioma:Inglês
Publicado em: 2016
Assuntos:
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC4930738/
https://ncbi.nlm.nih.gov/pubmed/26864210
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1078-0432.CCR-15-2184
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!